$RIGL
RIGEL PHARMACEUTICALS INC

2024 Q4 Form 10-Q Financial Statement

#000155837024014862 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $55.31M
YoY Change 96.58%
Cost Of Revenue $8.026M
YoY Change 532.97%
Gross Profit $47.28M
YoY Change 75.99%
Gross Profit Margin 85.49%
Selling, General & Admin $27.04M
YoY Change 8.8%
% of Gross Profit 57.2%
Research & Development $6.182M
YoY Change -4.53%
% of Gross Profit 13.08%
Depreciation & Amortization $611.0K
YoY Change 103.67%
% of Gross Profit 1.29%
Operating Expenses $33.23M
YoY Change 6.05%
Operating Profit $14.06M
YoY Change -414.8%
Interest Expense $2.060M
YoY Change 8.48%
% of Operating Profit 14.66%
Other Income/Expense, Net
YoY Change
Pretax Income $12.42M
YoY Change -318.3%
Income Tax
% Of Pretax Income
Net Earnings $12.42M
YoY Change -318.22%
Net Earnings / Revenue 22.46%
Basic Earnings Per Share $0.71
Diluted Earnings Per Share $0.70
COMMON SHARES
Basic Shares Outstanding 17.62M 17.59M
Diluted Shares Outstanding 17.65M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $61.11M
YoY Change -2.06%
Cash & Equivalents $51.69M
Short-Term Investments $9.422M
Other Short-Term Assets $9.994M
YoY Change 233.13%
Inventory $4.784M
Prepaid Expenses
Receivables $30.58M
Other Receivables $0.00
Total Short-Term Assets $106.5M
YoY Change 12.04%
LONG-TERM ASSETS
Property, Plant & Equipment $99.00K
YoY Change -47.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.761M
YoY Change -3.93%
Total Long-Term Assets $32.95M
YoY Change 62.33%
TOTAL ASSETS
Total Short-Term Assets $106.5M
Total Long-Term Assets $32.95M
Total Assets $139.4M
YoY Change 20.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.815M
YoY Change -52.31%
Accrued Expenses $21.95M
YoY Change 11.99%
Deferred Revenue $1.355M
YoY Change 0.0%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $54.31M
YoY Change 12.51%
LONG-TERM LIABILITIES
Long-Term Debt $59.76M
YoY Change 0.1%
Other Long-Term Liabilities $39.98M
YoY Change 3.15%
Total Long-Term Liabilities $39.98M
YoY Change 3.15%
TOTAL LIABILITIES
Total Short-Term Liabilities $54.31M
Total Long-Term Liabilities $39.98M
Total Liabilities $154.1M
YoY Change 4.69%
SHAREHOLDERS EQUITY
Retained Earnings -$1.404B
YoY Change -0.28%
Common Stock $1.390B
YoY Change 0.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$14.64M
YoY Change
Total Liabilities & Shareholders Equity $139.4M
YoY Change 20.89%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income $12.42M
YoY Change -318.22%
Depreciation, Depletion And Amortization $611.0K
YoY Change 103.67%
Cash From Operating Activities $21.68M
YoY Change -1694.04%
INVESTING ACTIVITIES
Capital Expenditures $10.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $3.812M
YoY Change -425.81%
Cash From Investing Activities $3.802M
YoY Change -424.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -9.842M
YoY Change 1031.26%
NET CHANGE
Cash From Operating Activities 21.68M
Cash From Investing Activities 3.802M
Cash From Financing Activities -9.842M
Net Change In Cash 15.64M
YoY Change -559.97%
FREE CASH FLOW
Cash From Operating Activities $21.68M
Capital Expenditures $10.00K
Free Cash Flow $21.67M
YoY Change -1693.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 rigl Net Sublease Income Expense
NetSubleaseIncomeExpense
CY2023Q3 rigl Net Sublease Income Expense
NetSubleaseIncomeExpense
rigl Net Sublease Income Expense
NetSubleaseIncomeExpense
rigl Net Sublease Income Expense
NetSubleaseIncomeExpense
dei Entity Registrant Name
EntityRegistrantName
RIGEL PHARMACEUTICALS INC
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001034842
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-29889
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3248524
dei Entity Address Address Line1
EntityAddressAddressLine1
611 Gateway Boulevard, Suite 900,
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
624-1100
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
RIGL
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17615040
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51692000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32786000
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
9422000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
24147000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
30575000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
30550000
CY2024Q3 us-gaap Inventory Net
InventoryNet
4784000
CY2023Q4 us-gaap Inventory Net
InventoryNet
5522000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9994000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6261000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
106467000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
99266000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
99000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
165000
CY2024Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
27687000
CY2023Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
13878000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
405000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
861000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4761000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3055000
CY2024Q3 us-gaap Assets
Assets
139419000
CY2023Q4 us-gaap Assets
Assets
117225000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3815000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7142000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7924000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8676000
CY2024Q3 rigl Accrued Research And Development Liability Current
AccruedResearchAndDevelopmentLiabilityCurrent
3593000
CY2023Q4 rigl Accrued Research And Development Liability Current
AccruedResearchAndDevelopmentLiabilityCurrent
3513000
CY2024Q3 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
5000000
CY2024Q3 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
22192000
CY2023Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
15684000
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
7229000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9967000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5334000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1355000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1355000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
466000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
692000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3642000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
54312000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
53267000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
285000
CY2024Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
59762000
CY2023Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
52373000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
39981000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
39944000
CY2024Q3 us-gaap Liabilities
Liabilities
154055000
CY2023Q4 us-gaap Liabilities
Liabilities
145869000
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
17000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
17000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1389742000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1378881000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
11000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
8000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1404406000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1407550000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-14636000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-28644000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
139419000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
117225000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55307000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28134000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
121682000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
81090000
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8026000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1268000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12858000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3320000
CY2024Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6182000
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6475000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
17748000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
21336000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
27043000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24856000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
83539000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
78891000
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
41251000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
32599000
us-gaap Costs And Expenses
CostsAndExpenses
114145000
us-gaap Costs And Expenses
CostsAndExpenses
103547000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
14056000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4465000
us-gaap Operating Income Loss
OperatingIncomeLoss
7537000
us-gaap Operating Income Loss
OperatingIncomeLoss
-22457000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
425000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
672000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1570000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1594000
CY2024Q3 us-gaap Interest Expense
InterestExpense
2060000
CY2023Q3 us-gaap Interest Expense
InterestExpense
1899000
us-gaap Interest Expense
InterestExpense
5963000
us-gaap Interest Expense
InterestExpense
4965000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
12421000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5692000
us-gaap Net Income Loss
NetIncomeLoss
3144000
us-gaap Net Income Loss
NetIncomeLoss
-25828000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.71
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.49
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.70
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.49
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17600000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17436000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17556000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17389000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17648000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17436000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17599000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17389000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
12421000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5692000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
3144000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25828000
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
20000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
10000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
3000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
138000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
12441000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5682000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3147000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25690000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-28644000
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8247000
CY2024Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-13000
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
89000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5144000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-31671000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1030000
CY2024Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-4000
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
252000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2539000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-29914000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
12421000
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
20000
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
158000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2679000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-14636000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-13616000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13536000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
126000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2768000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-24257000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6600000
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
2000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
554000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2186000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-28115000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5692000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
10000
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
8000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1955000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-31834000
us-gaap Profit Loss
ProfitLoss
3144000
us-gaap Profit Loss
ProfitLoss
-25828000
us-gaap Share Based Compensation
ShareBasedCompensation
10306000
us-gaap Share Based Compensation
ShareBasedCompensation
6873000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
23000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-376000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1624000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
945000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
433000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
219000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
25000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-16774000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1161000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1359000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3484000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5329000
rigl Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
456000
rigl Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
922000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3327000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
491000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-752000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-773000
rigl Increase Decrease In Accrued Research And Development Liability
IncreaseDecreaseInAccruedResearchAndDevelopmentLiability
80000
rigl Increase Decrease In Accrued Research And Development Liability
IncreaseDecreaseInAccruedResearchAndDevelopmentLiability
-1954000
rigl Revenue Reserves And Refund Liability
RevenueReservesAndRefundLiability
6508000
rigl Revenue Reserves And Refund Liability
RevenueReservesAndRefundLiability
2398000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
4566000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1455000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-511000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-966000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-14000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1043000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
16968000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
497000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
32950000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
35650000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
17562000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
18222000
rigl Payments To Acquire Capital Expenditures
PaymentsToAcquireCapitalExpenditures
10000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
360000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
15000000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
26000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
149000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15044000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2577000
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
19950000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
499000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
563000
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
10000000
rigl Payment Of Cost Share To Collaboration Partner
PaymentOfCostShareToCollaborationPartner
3605000
rigl Payment Of Cost Share To Collaboration Partner
PaymentOfCostShareToCollaborationPartner
2632000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-13106000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17881000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
18906000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
20955000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32786000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24459000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51692000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45414000
us-gaap Interest Paid Net
InterestPaidNet
5292000
us-gaap Interest Paid Net
InterestPaidNet
4167000
CY2024Q3 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
5000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates.</p>
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
61100000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
12421000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5692000
us-gaap Net Income Loss
NetIncomeLoss
3144000
us-gaap Net Income Loss
NetIncomeLoss
-25828000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17600000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17436000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17556000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17389000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17600000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17436000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17556000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17389000
CY2024Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
48000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
43000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17648000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17436000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17599000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17389000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.71
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.49
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.70
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.49
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3796000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3651000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3800000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3651000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55307000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28134000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
121682000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
81090000
rigl Sales Discounts And Allowances
SalesDiscountsAndAllowances
44600000
rigl Sales Discounts And Allowances
SalesDiscountsAndAllowances
29700000
CY2023Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
15684000
us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
44616000
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
38108000
CY2024Q3 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
22192000
CY2022Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
12145000
us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
29705000
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
27307000
CY2023Q3 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
14543000
rigl Contingent Payments Under Agreement
ContingentPaymentsUnderAgreement
1400000000
CY2021Q2 rigl Collaborative Arrangement Upfront Fee Received
CollaborativeArrangementUpfrontFeeReceived
125000000.0
rigl Right To Opt Out Of Agreement Number Of Periods
RightToOptOutOfAgreementNumberOfPeriods
2
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2644000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1943000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10306000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6873000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
158122
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
650000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1520361
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
1569000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4609000
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1811000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1876000
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5830000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1508000
CY2024Q3 rigl Inventory And Inventory Reported As Other Assets
InventoryAndInventoryReportedAsOtherAssets
9210000
CY2023Q4 rigl Inventory And Inventory Reported As Other Assets
InventoryAndInventoryReportedAsOtherAssets
7993000
CY2024Q3 us-gaap Inventory Net
InventoryNet
4784000
CY2023Q4 us-gaap Inventory Net
InventoryNet
5522000
CY2024Q3 rigl Inventory Reported As Other Assets
InventoryReportedAsOtherAssets
4426000
CY2023Q4 rigl Inventory Reported As Other Assets
InventoryReportedAsOtherAssets
2471000
CY2024Q3 rigl Inventory And Inventory Reported As Other Assets
InventoryAndInventoryReportedAsOtherAssets
9210000
CY2023Q4 rigl Inventory And Inventory Reported As Other Assets
InventoryAndInventoryReportedAsOtherAssets
7993000
CY2024Q3 us-gaap Advances On Inventory Purchases
AdvancesOnInventoryPurchases
3400000
CY2023Q4 us-gaap Advances On Inventory Purchases
AdvancesOnInventoryPurchases
0
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
30360000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
15000000
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2673000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1122000
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
27687000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
13878000
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1600000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
800000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
588000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
2351000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2351000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
2351000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
2351000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
17695000
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
27687000
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
61114000
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
56933000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51692000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32786000
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
9422000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
24147000
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
61114000
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
56933000
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
23180000
CY2024Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
23191000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
38993000
CY2023Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
39001000
rigl Cash Equivalents And Available For Sale Securities Weighted Average Maturity Period
CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P39D
CY2023 rigl Cash Equivalents And Available For Sale Securities Weighted Average Maturity Period
CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P82D
CY2024Q3 rigl Investments Credit Loss Expense
InvestmentsCreditLossExpense
0
CY2023Q4 rigl Investments Credit Loss Expense
InvestmentsCreditLossExpense
0
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
60000000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
60000000
CY2024Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
238000
CY2023Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
398000
CY2024Q3 rigl Debt Principal Outstanding Net Of Unamortized Debt Issuance Costs
DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts
59762000
CY2023Q4 rigl Debt Principal Outstanding Net Of Unamortized Debt Issuance Costs
DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts
59602000
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
7229000
CY2024Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
59762000
CY2023Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
52373000
CY2024Q3 us-gaap Loans Payable
LoansPayable
59762000
CY2023Q4 us-gaap Loans Payable
LoansPayable
59602000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
7500000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
30000000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
22500000
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
60000000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
166000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
166000
us-gaap Operating Lease Cost
OperatingLeaseCost
498000
us-gaap Operating Lease Cost
OperatingLeaseCost
944000
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
28000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
75000
us-gaap Variable Lease Cost
VariableLeaseCost
84000
us-gaap Variable Lease Cost
VariableLeaseCost
105000
CY2024Q3 us-gaap Lease Cost
LeaseCost
194000
CY2023Q3 us-gaap Lease Cost
LeaseCost
241000
us-gaap Lease Cost
LeaseCost
582000
us-gaap Lease Cost
LeaseCost
1049000
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
184000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
178000
us-gaap Operating Lease Payments
OperatingLeasePayments
552000
us-gaap Operating Lease Payments
OperatingLeasePayments
1352000
rigl Fixed Sublease Expense
FixedSubleaseExpense
365000
rigl Variable Sublease Expense
VariableSubleaseExpense
77000
us-gaap Sublease Income
SubleaseIncome
442000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
187000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
301000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
488000
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-014862-index-headers.html Edgar Link pending
0001558370-24-014862-index.html Edgar Link pending
0001558370-24-014862.txt Edgar Link pending
0001558370-24-014862-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rigl-20240930.xsd Edgar Link pending
rigl-20240930x10q.htm Edgar Link pending
rigl-20240930x10q007.jpg Edgar Link pending
rigl-20240930xex10d1.htm Edgar Link pending
rigl-20240930xex10d2.htm Edgar Link pending
rigl-20240930xex10d2001.jpg Edgar Link pending
rigl-20240930xex10d3.htm Edgar Link pending
rigl-20240930xex31d1.htm Edgar Link pending
rigl-20240930xex31d2.htm Edgar Link pending
rigl-20240930xex32d1.htm Edgar Link pending
rigl-20240930x10q_htm.xml Edgar Link completed
Show.js Edgar Link pending
rigl-20240930_cal.xml Edgar Link unprocessable
rigl-20240930_def.xml Edgar Link unprocessable
rigl-20240930_lab.xml Edgar Link unprocessable
rigl-20240930_pre.xml Edgar Link unprocessable